• Molecular NamePerphenazine
  • SynonymChlorperphenazine; Etaperazin; Etaperazine; Ethaperazine; Perfenazina; Perfenazine; Perphenazin; PZC
  • Weight403.978
  • Drugbank_IDDB00850
  • ACS_NO58-39-9
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)4.17
  • pka7.94
  • LogD (pH=7, predicted)3.24
  • Solubility (experiment)0.0283 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.67
  • LogSw (predicted, AB/LogsW2.0)0.03
  • Sw (mg/ml) (predicted, ACD/Labs)0.02
  • No.of HBond Donors1
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds6
  • TPSA55.25
  • StatusFDA approved
  • AdministrationOral and IM
  • PharmacologyA typical antipsychotic drug.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability40.0
  • Protein binding90.0
  • Volume of distribution (VD)10 to 35 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmExtensively metabolized in liver to a number of metabolites mediated by CYP2D6 and is subject to genetic polymorphism (7% to 10% of white patients, low percentage of Asian patients); therefore, they are poor metabolizers of CYP2D6 and will then metabolize the drug more slowly.
  • Half life8~12 h
  • Excretionbiliar
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include stupor or coma, and children may have convulsive seizures. Signs of arousal may not occur for 48 hours.
  • LD50 (rat)LD50=318 mg/kg
  • LD50 (mouse)LD50=64 mg/kg